Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

RTX's Collins Aerospace initiates powertrain testing for Clean Aviation SWITCH project at the Grid

Validation of key systems at the Grid will support future testing of full-scale hybrid-electric Pratt & Whitney GTF™ engine demonstrator ROCKFORD, Ill., March 16, 2026 /PRNewswire/ -- Collins Aerospace has begun initial testing of the electric motor drive systems for the European Union's Clean Aviation SWITCH project, a key step towards demonstrating the hybrid-electric technology on a full-scale Pratt & Whitney GTF™ engine.

RTX's Raytheon completes $115 million expansion of Alabama missile integration facility

Expansion to increase facility's integration and delivery capacity by more than 50% HUNTSVILLE, Ala., March 13, 2026 /PRNewswire/ -- Raytheon, an RTX (NYSE: RTX) business, has completed a 26,000 square-foot expansion of its Redstone Raytheon Missile Integration Facility, backed by a $115 million capital investment that will increase the facility's integration and delivery capacity by over 50% and grow the company's footprint in the state to more than 2,200 employees.

RTX's Pratt & Whitney awarded follow-on contract to supply TJ150 engines for Leidos' small cruise missile

Contract will provide TJ150 turbojet engines for the effector EAST HARTFORD, Conn., March 10, 2026 /PRNewswire/ -- Pratt & Whitney, an RTX (NYSE: RTX) business, was awarded a follow-on contract from Leidos Dynetics to supply TJ150 engines for their AGM-190A small cruise missile.

XtalPi's AI + Robotics Platform Powers First Clinical Milestone for ReviR's Rare Neurological Drug RTX-117

RTX-117 is an investigational small molecule designed to modulate the Integrated Stress Response (ISR) pathway, with the goal of restoring protein translation homeostasis implicated in Charcot-Marie-Tooth disease (CMT) and Vanishing White Matter disease (VWM) ReviR has dosed the first participant in a Phase 1 trial of RTX-117, initially evaluating safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) in healthy participants Milestone marks the clinical entry of a potential first-in-class therapy for CMT and VWM co-discovered using XtalPi's AI and robotics drug R&D platform CAMBRIDGE, Mass. & SHANGHAI, March 2, 2026 /PRNewswire/ -- XtalPi, a global leading AI- and robotics-driven drug discovery platform, today noted a key milestone in its collaboration with ReviR Therapeutics: dosing of the first participant in the Phase 1 clinical trial of RTX-117, an investigational small molecule being developed for Charcot-Marie-Tooth disease (CMT) and Vanishing White Matter disease (VWM).